文献速递胸部肿瘤

携带多重分子改变的肺癌患者的特征与结局:IFCT Biomarkers France 研究结果

Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France.
PubMed 文献 · J Thorac Oncol · 2017-02-09

基于法国Biomarkers France数据库17664例患者,多重基因组改变患病率约0.9%,涉及KRAS、PIK3CA和EGFR;双突变未降低总生存,但EGFR/KRAS和EGFR/PIK3CA双突变患者一线治疗的无进展生存劣于仅EGFR突变者,针对主导癌基因的靶向治疗在有限例数中似乎仍具活性。

要点

  • 多重分子改变在晚期非小细胞肺癌中约占0.9%,以KRAS、PIK3CA和EGFR组合为主。
  • 双突变不影响总生存,但EGFR/KRAS和EGFR/PIK3CA双突变患者无进展生存劣于仅EGFR突变者。
  • KRAS合并其他改变的患者一线化疗疗效与仅KRAS突变者相似。

核心结论

  • 约1%患者携带多重分子改变,应重新考虑突变互斥的教条;双突变不降低总生存但改变EGFR突变患者一线治疗的无进展生存,针对主导癌基因的治疗在有限例数中似乎通常仍具活性。

研究设计与样本

  • 基于法国Biomarkers France数据库的回顾性分析,纳入17664例患者,评估多重分子改变的患病率、关联、对预后(总生存)及对靶向或常规治疗反应(无进展生存和客观缓解率)的影响,并与单突变或无突变患者比较。

主要发现

  • 共鉴定162例(0.9%)双分子改变患者和3例三重突变患者。
  • 多重分子改变主要涉及KRAS(67.3%)、PIK3CA(53.3%)和EGFR(42.4%)。
  • 多重改变患者更多为男性(56.4%)、从不吸烟者(25.8% vs 34.7%,p < 0.001)和腺癌(83.6%)。
  • 单突变与多重改变患者的总生存无差异。
  • EGFR/KRAS和EGFR/PIK3CA突变患者无进展生存劣于仅EGFR突变者(7.1和7.1 vs 14.9个月,p = 0.02和0.002)。

临床怎么用

  • 作者认为,针对主导癌基因的治疗在有限例数中似乎通常仍具活性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Little is known about the prevalence, prognosis, and response to treatment of advanced NSCLC harboring multiple genomic alterations. METHODS: The French Biomarkers France database, which includes 17,664 patients, was used. The prevalence of multiple alterations, their associations, their impact on prognosis (overall survival [OS]), and their response to targeted or conventional treatments (progression-free survival [PFS] and objective response rate) were assessed and compared with those of patients harboring single or no mutation. RESULTS: We identified 162 patients (0.9%) with double alterations and three with triple mutations. Multiple molecular alterations preferentially involved KRAS (67.3%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) (53.3%), and EGFR (42.4%). Patients with multiple alterations were more likely to be male (56.4%), be never-smokers (25.8 versus 34.7%, p < 0.001), and exhibit adenocarcinomas (83.6%). OS did not differ between single and multiple alterations. Patients with EGFR/KRAS and EGFR/PIK3CA mutations experienced worse PFS than did patients with only EGFR mutations (7.1 and 7.1 versus 14.9 months, p = 0.02 and 0.002, respectively). Concomitant mutations in patients harboring anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement bore little impact on OS (17.7 versus 20.3 months, p = 0.57) or PFS (10.3 versus 12.1 months, p = 0.93). Patients harboring KRAS mutations plus another alteration had an OS time (13.4 versus 11.2 months, p = 0.28), PFS time (6.4 versus 7.2 months, p = 0.78), and objective response rate under first-line chemotherapy (41.7% versus 37.2%) similar to those of patients harboring KRAS mutations only. CONCLUSIONS: With almost 1% of patients harboring multiple alterations, the dogma of mutually exclusive mutations should be reconsidered. Although double mutations do not decrease OS, they do alter PFS under first-line treatment for patients with EGFR mutations. Among limited numbers of patients, therapies targeting the dominant oncogene seem to usually remain active.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Guibert N, Barlesi F, Descourt R, et al. Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France. J Thorac Oncol. 2017. PMID: 28189832. doi:10.1016/j.jtho.2017.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。